Daniel Sontheimer, MD, MBA
In elderly patients with coronary heart disease (CHD), do statins reduce all-cause mortality?
MEDLINE, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, and ACP Journal Club (all to 2007); conference abstracts; reference lists; and unpublished data from investigators.
Randomized controlled trials (RCTs) in any language that compared statins with placebo in ≥ 50 patients ≥ 65 years of age with documented CHD at randomization and evaluated all-cause mortality, CHD mortality, nonfatal myocardial infarction (MI), revascularization, or stroke at ≥ 6 months of follow-up. 9 RCTs (n = 19 569, age range 65 to 82 y) met the selection criteria.
All-cause mortality, CHD mortality, nonfatal MI, revascularization, and stroke.
Meta-analysis showed that statins reduced all-cause mortality, CHD mortality, nonfatal MI, revascularization, and stroke compared with placebo (Table).
Statins reduce all-cause mortality in elderly patients with coronary heart disease.
Statins vs placebo in elderly patients with coronary heart disease (CHD)*
*MI = myocardial infarction; other abbreviations defined in Glossary. Weighted event rates, RRR, and CI calculated from control event rates and relative risks in article.
†NNT and CI provided in article; based on Bayesian posterior estimates.
Sontheimer D. Review: Statins reduce all-cause mortality in elderly patients with coronary heart disease. Ann Intern Med. ;148:JC3–3. doi: 10.7326/0003-4819-148-10-200805200-02003
Download citation file:
Published: Ann Intern Med. 2008;148(10):JC3-3.
Cardiology, Coronary Heart Disease, Coronary Risk Factors, Dyslipidemia, Geriatric Medicine.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use